Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
作者： J. Silvain , F. Beygui , O. Barthelemy , C. Pollack , M. Cohen
DOI: 10.1136/BMJ.E553
关键词:
摘要: Objective To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention. Design Systematic review meta-analysis. Data sources Medline Cochrane database systematic reviews, January 1996 to May 2011. Study selection Randomised non-randomised studies comparing intervention reporting on both mortality (efficacy end point) major bleeding (safety outcomes. extraction Sample size, characteristics, outcomes, extracted independently analysed. synthesis 23 trials representing 30 966 patients were identified, including 10 243 (33.1%) undergoing primary for ST elevation myocardial infarction, 8750 (28.2%) secondary after fibrinolysis, 11 973 (38.7%) non-ST acute syndrome or stable scheduled A total 13 943 (45.0%) received 17 023 (55.0%) heparin. Enoxaparin was associated significant reductions in death (relative risk 0.66, 95% confidence interval 0.57 0.76; P Conclusion seems be superior reducing outcomes particularly infarction.
sci-hub.se 参考文章(64)
Salim Yusuf, Shamir R Mehta, Susan Chrolavicius, Janine Pogue, Christopher B Granger, Andrzej Budaj, Ron JG Peters, Jean-Pierre Bassand, Lars Wallentin, Campbell Joyner, Keith AA Fox, None, Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA. ,vol. 295, pp. 1519- 1530 ,(2006) , 10.1001/JAMA.295.13.JOC60038
Shamir R. Mehta, Christopher B. Granger, John W. Eikelboom, Jean-Pierre Bassand, Lars Wallentin, David P. Faxon, Ron J.G. Peters, Andrzej Budaj, Rizwan Afzal, Susan Chrolavicius, Keith A.A. Fox, Salim Yusuf, Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Journal of the American College of Cardiology. ,vol. 50, pp. 1742- 1751 ,(2007) , 10.1016/J.JACC.2007.07.042
C. Michael Gibson, David A. Morrow, Sabina A. Murphy, Theresa M. Palabrica, Lisa K. Jennings, Peter H. Stone, Henry H. Lui, Thomas Bulle, Nasser Lakkis, Richard Kovach, David J. Cohen, Polly Fish, Carolyn H. McCabe, Eugene Braunwald, A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents Journal of the American College of Cardiology. ,vol. 47, pp. 2364- 2373 ,(2006) , 10.1016/J.JACC.2005.12.077
Gilles Montalescot, Richard Gallo, Harvey D White, Marc Cohen, Ph Gabriel Steg, Philip EG Aylward, Christoph Bode, Massimo Chiariello, Spencer B King, Robert A Harrington, Walter J Desmet, Carlos Macaya, Steven R Steinhubl, STEEPLE Investigators, None, Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention : 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial Jacc-cardiovascular Interventions. ,vol. 2, pp. 1083- 1091 ,(2009) , 10.1016/J.JCIN.2009.08.016
Lawrence O'Meallie, Benjamin Y C Cheong, José G Díez, James J Ferguson, Hector M Medina, Safety of Enoxaparin versus Unfractionated Heparin during Percutaneous Coronary Intervention Texas Heart Institute Journal. ,vol. 36, pp. 98- 103 ,(2009)
Marc Cohen, Pierre Théroux, Steven Borzak, Martin J. Frey, Harvey D. White, W. Van Mieghem, Fred Senatore, Joy Lis, Robin Mukherjee, Kathy Harris, Frederique Bigonzi, Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study American Heart Journal. ,vol. 144, pp. 470- 477 ,(2002) , 10.1067/MHJ.2002.126115
Paola Sanchez-Pena, Jean-Sebastien Hulot, Saik Urien, Annick Ankri, Jean-Philippe Collet, Remi Choussat, Philippe Lechat, Gilles Montalescot, Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis British Journal of Clinical Pharmacology. ,vol. 60, pp. 364- 373 ,(2005) , 10.1111/J.1365-2125.2005.02452.X
Salim Yusuf, Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes An Individual Patient–Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials Circulation. ,vol. 118, pp. 2038- 2046 ,(2008) , 10.1161/CIRCULATIONAHA.108.789479
Madhu K. Natarajan, James L. Velianou, Alexander G.G. Turpie, Shamir R. Mehta, Dominic Raco, David M. Goodhart, Rizwan Afzal, Jeffrey S. Ginsberg, A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. American Heart Journal. ,vol. 151, pp. 175- 175 ,(2006) , 10.1016/J.AHJ.2005.06.020